Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
SXTP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.42 - $7.19
Previous CloseN/A
Volume13.44M
Average Volume (3M)4.41M
Market Cap
$3.48M
Enterprise Value$7.69M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.94
Shares Outstanding7,364,554
10 Day Avg. Volume753,968
30 Day Avg. Volume4,409,570
Standard Deviation0.34
R-Squared0.21
Alpha-0.18
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.23
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap2.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-34.80
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$3.40Price Target Upside655.56% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Progress60 Degrees announced a patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of Arakoda for the treatment and prevention of babesiosis.
Market PotentialArakoda has been granted FDA Orphan Drug Designation for the treatment of babesiosis, enhancing its potential market value for a rare disease.
Sales GrowthArakoda boxes sold increased 140% YoY, indicating strong sales growth and market demand for the product.
Bears Say
Financial NeedsThe company has been raising equity capital to extend its financial runway, indicating the need for additional funds in the near future.
Market InsightThere is little insight into the malaria market currently, with the analyst awaiting findings from the company's pilot program for more information.
Uncertainty In EvaluationIt is difficult to evaluate the company prior to data from the clinical babesiosis program.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.97% Insiders
0.09% Mutual Funds
1.36% Other Institutional Investors
93.57% Public Companies and Individual Investors
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $0.42 and its highest was $7.18 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.48M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
60 Degrees Pharmaceuticals, Inc. released its earnings results on Aug 14, 2024. The company reported -$4.235 earnings per share for the quarter, the consensus estimate of -$4.235 by $0.
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 7,364,554 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
60 Degrees Pharmaceuticals, Inc. reported an EPS of -$4.235 in its last earnings report, expectations of -$4.235. Following the earnings report the stock price went down -3.061%.
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
---
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.
---
SXTP Stock 12 Month Forecast
Average Price Target
$3.40
▲(655.56% Upside)
Technical Analysis
Best Analysts Covering SXTP
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-76.10%
reiterated a buy rating 3 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.10% per trade.
---